Prognostic implications of HER2 heterogeneity in gastric cancer

Shigenobu Motoshima; Koji Yonemoto; Hideki Kamei; Michi Morita; Rin Yamaguchi

doi:10.18632/oncotarget.24265

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Prognostic implications of HER2 heterogeneity in gastric cancer

Shigenobu Motoshima, Koji Yonemoto, Hideki Kamei, Michi Morita and Rin Yamaguchi _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2018; 9:9262-9272. https://doi.org/10.18632/oncotarget.24265

Metrics: PDF 1747 views | HTML 3023 views | ?

Abstract

Shigenobu Motoshima1,2, Koji Yonemoto3, Hideki Kamei4, Michi Morita5 and Rin Yamaguchi6

1Biostatistics Center, Graduate School of Medicine, Kurume University, Kurume, Fukuoka, Japan

2Department of Clinical Laboratory, Kokura Medical Center, Kitakyushu, Fukuoka, Japan

3Advanced Medical Research Center, Faculty of Medicine, University of the Ryukyus, Nishihara, Okinawa, Japan

4Department of Surgery, Japan Community Health Care Organization Kurume General Hospital, Kurume, Fukuoka, Japan

5Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan

6Department of Pathology and Laboratory Medicine, Kurume University Medical Center, Kurume, Fukuoka, Japan

Correspondence to:

Rin Yamaguchi, email: [email protected]

Keywords: gastric cancer; HER2; intratumoral heterogeneity; prognosis; trastuzumab

Received: July 11, 2017 Accepted: January 09, 2018 Published: January 18, 2018

ABSTRACT

The prognostic implications of human epidermal growth receptor 2 (HER2) heterogeneity in gastric cancer (GC) are not well established. Therefore, the aim of the present study was to determine to the effect of HER2 status on the prognosis of GC patients. We retrieved data on 248 pathologically-confirmed, consecutive patients with primary adenocarcinoma of the stomach or gastro-esophageal junction who underwent surgical resection at Kurume University Medical Center between July 2000 and December 2012. HER2 status was classified as HER2 positive or negative and HER2 heterogeneity or homogeneity. The endpoint was overall survival (OS), which was compared using the generalized Wilcoxon test. HER2 status was positive in 36 patients (14.5%) and negative in 212 patients (85.5%). Among the 36 HER2 positive patients, 25 patients (69.4%) had HER2 heterogeneity and the remaining 11 patients (30.6%) had HER2 homogeneity. Among the 141 patients with stage III or IV disease, the prognosis of the HER2 homogeneity group was significantly worse than that of the HER2 heterogeneity group (p = 0.019; median OS 193 and 831 days, respectively). The prognosis was not significantly different between the HER2 positive group and the HER2 negative group (p = 0.84; median OS 552 and 556 days, respectively). The present study was conducted with small samples, however, the results of the study suggest that HER2 homogeneity but not HER2 positivity may represent a prognostic indicator in GC.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24265

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Prognostic implications of HER2 heterogeneity in gastric cancer

Abstract